|
|
EN

  • 業務谘詢

    中國：

    Email: marketing@yakkaa.com

    業務谘詢專線：400-780-8018

    （僅限服務谘詢，其他事宜請撥打川沙總部電話）

    川沙總部電話: +86 (21) 5859-1500

    海外：

    +1(626)986-9880(U.S. - West Coast)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在線留言×
點擊切換
Customer Center
客戶中心
Jul 05,2023
合成具有體內抗腫瘤活性的強效PD-L1抑製劑，並進行生物學評價和機製研究。PK研究通過hjc黄金城進行
PD-1 and PD-L1 have been very successful for the treatment of various tumors, including NSCLC, urothelial cancer, melanoma, head and neck squamous cell cancer, and lymphoma. Researchers identified compound L7 as a potent PD-L1 inhibitor that blocked PD-1/PD-L1 interaction. Pharmacokinetic (PK) studies demonstrated that L7 was orally bioavailable. PK studies were conducted by Medicilon.
查看更多
合成具有體內抗腫瘤活性的強效PD-L1抑製劑，並進行生物學評價和機製研究。PK研究通過hjc黄金城進行
Jul 05,2023
SLL-1206是一種κ阿片受體激動劑，具有顯著改善的理化和藥代動力學特性。作者感謝hjc黄金城對SLL-1206進行的藥代動力學研究
The search for selective kappa opioid receptor (κOR) agonists with an improved safety profile is an area of interest in opioid research. SLL-1206 is a κOR agonist with single-digit nanomolar activities. SLL-1206 exhibits substantially improved physicochemical and pharmacokinetic properties, and reduces central nervous system effects. The s are grateful to Medicilon Preclinical Research LLC. for pharmacokinetic studies on SLL-1206.
查看更多
SLL-1206是一種κ阿片受體激動劑，具有顯著改善的理化和藥代動力學特性。作者感謝hjc黄金城對SLL-1206進行的藥代動力學研究
Jul 05,2023
苯並咪唑衍生物XY123是一種口服有效的選擇性RORγ反向激動劑。在本研究中，所有肝微粒體測定均通過hjc黄金城進行
Receptor-related orphan receptor γ (RORγ) has emerged as an attractive therapeutic target for the treatment of cancer and inflammatory diseases. XY123 potently inhibits the RORγ transcription activity with an IC50 value of 64 nM. XY123 demonstrates good metabolic stability and a pharmacokinetics property with reasonable oral bioavailability (32.41%) and moderate half-life (4.98 h). All liver microsome assays were performed by Medicilon.
查看更多
苯並咪唑衍生物XY123是一種口服有效的選擇性RORγ反向激動劑。在本研究中，所有肝微粒體測定均通過hjc黄金城進行
Jul 05,2023
zapERtrap：光調節的內質網釋放係統揭示了意想不到的神經元運輸途徑，Zapalog的合成通過hjc黄金城進行
zapERtrap opens the door to previously unapproachable questions concerning how proteins are processed, trafficked, and secreted in space and time in complex cellular environments. zapERtrap relies on a small-molecule protein dimerizer zapalog, which consists of the antibiotic trimethoprim tethered to a synthetic ligand of FK506-binding protein through a photocleavable linker. Synthesis of zapalog was performed by Medicilon.
查看更多
zapERtrap：光調節的內質網釋放係統揭示了意想不到的神經元運輸途徑，Zapalog的合成通過hjc黄金城進行
Jul 05,2023
端錨聚合酶1/2影響WNT/β-連環蛋白和Hippo信號通路，這些信號通路涉及包括腫瘤在內的多種疾病
Tankyrase 1 and 2 (TNKS1/2) impact the WNT/β-catenin and Hippo signaling pathways that are involved in numerous human disease conditions including cancer. OM-153 shows picomolar IC50 inhibition in a cellular (HEK293) WNT/β-catenin signaling reporter assay, no off-target liabilities, overall favorable ADME properties, and an improved pharmacokinetic profile in mice. The pharmacokinetic analyses in mice were performed according to the standard protocols of Medicilon.
查看更多
端錨聚合酶1/2影響WNT/β-連環蛋白和Hippo信號通路，這些信號通路涉及包括腫瘤在內的多種疾病
Jul 05,2023
設計合成和評估用於治療前列腺癌的CBP溴結構域抑製劑。PK評估、肝微粒體穩定性測定和Caco-2滲透性測定通過hjc黄金城進行
Prostate cancer (PCa) is one of the most commonly diagnosed cancers and the leading cause of cancer mortalities in men. CREB (cyclic-AMP responsive element binding protein) binding protein (CBP) is a potential target for prostate cancer treatment. Researchers designed 1-(Indolizin-3-yl)ethan-1-ones as CBP bromodomain inhibitors for the treatment of prostate cancer. Pharmacokinetic properties evaluation were analyzed by Medicilon. Liver microsomal stability assay were performed at Medicilon. Caco-2 permeability assay was analyzed by Medicilon.
查看更多
設計合成和評估用於治療前列腺癌的CBP溴結構域抑製劑。PK評估、肝微粒體穩定性測定和Caco-2滲透性測定通過hjc黄金城進行
Jul 05,2023
研究人員使用RZ-2994來表征抑製SHMT1/2在T細胞急性淋巴細胞白血病 (T-ALL) 中的作用，RZ-2994通過hjc黄金城定製合成
​Despite progress in the treatment of T-cell acute lymphoblastic leukemia (T-ALL) has limited treatment options, particularly in the setting of relapsed/refractory disease. Researchers used SHMT1/2 inhibitor RZ-2994 to characterize the effect of inhibiting SHMT1/2 in T-ALL. Loss of both SHMT1/2 is necessary for impaired growth and cell cycle arrest, with suppression of SHMT1/2 inhibiting leukemia progression. RZ-2994 also decreases leukemia burden in vivo. RZ-2994 was obtained from Medicilon. Medicilon offers a full range of chemical services covering all phases of your project. Customers can work with us either through FFS or FTE.
查看更多
研究人員使用RZ-2994來表征抑製SHMT1/2在T細胞急性淋巴細胞白血病 (T-ALL) 中的作用，RZ-2994通過hjc黄金城定製合成
Jul 05,2023
研究人員開發了一種高特異性的CDC7抑製劑TAK-931作為臨床腫瘤治療劑，抗腫瘤藥效研究通過hjc黄金城進行
Cell division cycle 7 (CDC7) plays important roles in DNA replication. Researchers developed a highly specific CDC7 inhibitor, TAK-931, as a clinical cancer therapeutic agent. The antitumor efficacy studies in PDX models were performed at Medicilon. Medicilon has established a complete evaluation system for preclinical anti-tumor efficacy, and has more than 200 different types of tumor efficacy models.
查看更多
研究人員開發了一種高特異性的CDC7抑製劑TAK-931作為臨床腫瘤治療劑，抗腫瘤藥效研究通過hjc黄金城進行
Jul 05,2023
研究新型多靶點抗高血壓藥MT-1207的藥理學特性，評價MT-1207的結合抑製活性通過hjc黄金城進行
Hypertension is a serious public health problem worldwide. MT-1207 is a chemical entity that has entered into clinical trial as antihypertensive agent. MT-1207 potently inhibits adrenergic α1A, α1B, α1D, and 5-HT2A receptors with Ki<1 nM in a panel of enzyme activity or radioligand binding assays. The binding inhibition activities of MT-1207 were evaluated by Medicilon.
查看更多
研究新型多靶點抗高血壓藥MT-1207的藥理學特性，評價MT-1207的結合抑製活性通過hjc黄金城進行
Jul 05,2023
設計、合成和評估具有體內抗炎活性的RIPK1抑製劑，PK研究通過hjc黄金城進行
RIPK1 plays a key role in the necroptosis pathway that regulates inflammatory signaling and cell death in various diseases, including inflammatory and neurodegenerative diseases. Herein, researchers report a series of potent RIPK1 inhibitors, represented by compound 70. Compound 70 possesses favorable pharmacokinetic parameters with moderate clearance and good oral bioavailability in SD rat. The pharmacokinetic parameters were determined at Medicilon using male SD rats (3 rats per group, 4 groups).
查看更多
設計、合成和評估具有體內抗炎活性的RIPK1抑製劑，PK研究通過hjc黄金城進行